Future prospects for treatment of hemoglobinopathies.
Strategies for the treatment of sickle cell anemia and beta-thalassemia are founded on the knowledge that these disorders result from structural or functional defects in an adult gene for which an intact fetal counterpart exists. During the past decade, several pharmacologic agents have been investigated for their potential to ameliorate sickle cell anemia and beta-thalassemia by increasing the synthesis of fetal hemoglobin in adults. Progress in understanding globin gene regulation is now being combined with advances in retrovirus-mediated gene transfer, and the once-distant goal of providing gene therapy for hemoglobinopathies is rapidly approaching reality.
D000328:Adult; D000755:Anemia, Sickle Cell / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D005319:Fetal Hemoglobin / Q000096:biosynthesis / Q000235:genetics; D015316:Genetic Therapy; D005822:Genetic Vectors; D006454:Hemoglobins / Q000235:genetics; D006801:Humans; D010957:Plasmids; D012190:Retroviridae / Q000235:genetics; D012191:Retroviridae Proteins / Q000627:therapeutic use; D014162:Transfection; D017086:beta-Thalassemia / Q000235:genetics / Q000378:metabolism / Q000628:therapy*
D006454:Hemoglobins; D012191:Retroviridae Proteins; D005319:Fetal Hemoglobin